A score may show who is helped by one brain tumor drug
Original title: Integration of MRI radiomics with immune profiling to predict response to CDK6 inhibitors in high-grade glioma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This only looked back at people's old records, so it is not proven yet.
The short version
Doctors built a score to tell who might be helped by a certain drug.
What was studied. Doctors looked back at records of 116 adults with fast growing brain tumors. They built a score from MRI scans and from immune cells in the blood.
What they found. In a matched group of 108 people, the drug did not clearly help everyone. Tumors grew again after 4.8 months with the drug and 3.5 months without it. People with a high score did better, and their tumors shrank in 33.3% of cases, against 5.6% in those not given the drug.
What this means, and what it doesn't
What it could mean: If this holds up, a scan and a blood test might help pick the right people for this drug. Others could be spared a drug that may not help them.
What it doesn't mean: This does not mean the drug works for most people. Doctors looked back at old records, so this is early work. The score is not used in normal care today. It still needs testing in new trials. This is not a cure and not a promise.
Source: PubMed, September 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.